Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Aegis Awarded Patent for Interferon Alpha, Beta, and Gamma Formulations that Eliminate Aggregation and Associated Immunogenicity and are Suitable for Non-Invasive or Injectable Delivery

SAN DIEGO, CA  January 4, 2012/MarketWire– Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,084,022 providing broad protection for stabilized formulations of alpha, beta, and gamma interferon suitable for non-invasive metered nasal spray delivery or traditional injection. Examples of approved interferon drugs include Betaferon®/Betaseron®/ (Bayer), Avonex®/ (Biogen Idec), Rebif®/ (EMD Serono/Pfizer), Laroféron (Roche), Roferon-A (Roche), Canferon® (Takeda) and Actimmune® (Genentech). The beta interferons are indicated for the treatment of multiple sclerosis and the alpha interferons are used for treatment of chronic hepatitis C and hairy cell leukemia.  Gamma interferon is used in the treatment of chronic granulomatous disease and severe malignant osteopetrosis.

Aegis will begin seeking potential licensees for this most recently issued patent for its ProTek® protein stabilization and immunogenicity reduction technology. Other issued ProTek® related patents provide for non-invasive delivery and stabilization of GLP-1 analogs, human growth hormone, and PTH, with others pending.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability.  Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in most protein injectable drugs.

For more information about Aegis, please visit:  http://www.aegisthera.com.